Following an initial negative biopsy, there is an ongoing need for strategies to improve patient selection for repeat biopsy as well as the diagnostic yield from repeat biopsies.
As a collaborative Initiative of the American Urological Association and the Society of Abdominal Radiology's Prostate Cancer Disease-Focused Panel, an expert panel of urologists and radiologists conducted a literature review and formed consensus statements regarding the role of prostate MRI and MRI-targeted biopsy in patients with a negative biopsy, which are summarized in this review.
s: The panel recognizes that many options exist for men with a previously negative biopsy. If a biopsy is recommended, prostate MRI and subsequent MRI-targeted cores appear to facilitate the detection of CS disease over standardized repeat biopsy. Thus, when high-quality prostate MRI is available, it should be strongly considered in any patient with a prior negative biopsy who has persistent clinical suspicion for prostate cancer and who is under evaluation for a possible repeat biopsy. The decision whether to perform MRI in this setting must also take into account results of any other biomarkers, the cost of the examination, as well as availability of high quality prostate MRI interpretation. If MRI is done, it should be performed, interpreted, and reported in accordance with PI-RADS V2 guidelines. Experience by the reporting radiologist and biopsy operator are required to achieve optimal results and practices integrating prostate MRI into patient management are advised to implement quality assurance programs to monitor targeted biopsy results. Patients receiving a PI-RADS assessment category of 3-5 warrant repeat biopsy with image guided targeting. While TRUS-MRI fusion or in-bore MRI-targeting may be valuable for more reliable targeting, especially for MRI lesions that are small or in difficult locations, in the absence of such targeting technologies, cognitive (visual) targeting remains a reasonable approach in skilled hands. At least two targeted cores should be obtained from each MRI-defined target. Given a number of studies showing a proportion of missed CS cancers by MRI-targeted cores, a case-specific decision must be made whether to also perform concurrent systematic sampling. However, performing solely targeted biopsy should only should be considered once quality assurance efforts have validated the performance of prostate MRI interpretations with results consistent with the published literature. In patients with a negative or low-suspicion MRI (PI-RADS assessment category of 1 or 2, respectively), other ancillary markers (i.e., PSA, PSAD, PSAV, PCA3, PHI, 4K) may be of value to identify patients warranting repeat systematic biopsy, although further data is needed on this topic. If a repeat biopsy is deferred on the basis of the MRI findings, then continued clinical and laboratory follow-up is advised and consideration should be given to incorporating repeat MRI in this diagnostic surveillance regimen.
The Journal of urology. 2016 Jun 16 [Epub ahead of print]
Andrew B Rosenkrantz, Sadhna Verma, Peter Choyke, Steven C Eberhardt, Scott E Eggener, Krishnanath Gaitonde, Masoom A Haider, Daniel J Margolis, Leonard S Marks, Peter Pinto, Geoffrey A Sonn, Samir S Taneja
Department of Radiology, NYU Langone Medical Center. Electronic address: ., Department of Radiology, University of Cincinnati, College of Medicine., Molecular Imaging Program, National Cancer Institute, National Institutes of Health., Department of Radiology, University of New Mexico., Department of Urology, University of Chicago Medicine., Department of Urology, University of Cincinnati, College of Medicine., Department of Medical Imaging, Sunnybrook Health Sciences Center, University of Toronto., Department of Radiology, David Geffen School of Medicine at UCLA., Department of Urology, David Geffen School of Medicine at UCLA., Urologic Oncology Branch, National Cancer Institute & NIH Clinical Center, National Institutes of Health., Department of Urology, Stanford University School of Medicine., Department of Urologic Oncology, NYU Langone Medical Center.